Clinical Trial Update: Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) [Phase 2]

View source ↗

Summary

The document notes the completion of a Phase 2 trial of ofatumumab in relapsed nodular lymphocyte predominant Hodgkin lymphoma conducted by the University of Co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nodular Lymphocyte-predominant Hodgkin Lymphoma

Drugs mentioned

• Arzerra (ofatumumab)

Snippet

Sponsor: University of Cologne | Conditions: Relapsed NLPHL | Phase 2 | Status: COMPLETED